New Zealand's PHARMAC has released its updated technical assessment of Vertex's cystic fibrosis therapy TRIKAFTA saying it provides patients with the equivalent of 27 additional years at full health when compared to the treatments it currently funds.

Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 29 August
August 29, 2025 - - Podcast -
Government pressed on diabetes inquiry response as obesity costs soar
August 29, 2025 - - Latest News -
NDIS quarterly report presents a positive picture, but questions remain
August 29, 2025 - - Latest News -
Wesfarmers Health delivers growth as Priceline drives consumer momentum
August 29, 2025 - - Latest News -
'We can evade reality, but we cannot evade the consequences of evading reality'
August 29, 2025 - - Latest News -
Australians fear the loss of independence as vision health concerns rise
August 29, 2025 - - Latest News -
Coalition turns debate on cheaper medicines Bill to HTA reform delays
August 27, 2025 - - Latest News